

Accepted Manuscript

Benzimidazole Derivatives as Potential Dual Inhibitors for PARP-1 and DHODH

Iskandar Abdullah, Chee Chin Fei, Lee Yean Kee, Siva Sanjeeva Rao Thunuguntla, K. Satish Reddy, Kavitha Nellore, Thomas Antony, Jitender Verma, Kong Wai Mun, Shatrah Othman, Hosahalli Subramanya, Noorsaadah Abd Rahman


PII: S0968-0896(15)00473-3
DOI: <http://dx.doi.org/10.1016/j.bmc.2015.05.051>
Reference: BMC 12347

To appear in: *Bioorganic & Medicinal Chemistry*

Received Date: 8 April 2015
Revised Date: 28 May 2015
Accepted Date: 29 May 2015

Please cite this article as: Abdullah, I., Fei, C.C., Kee, L.Y., Thunuguntla, S.S.R., Satish Reddy, K., Nellore, K., Antony, T., Verma, J., Mun, K.W., Othman, S., Subramanya, H., Rahman, N.A., Benzimidazole Derivatives as Potential Dual Inhibitors for PARP-1 and DHODH, *Bioorganic & Medicinal Chemistry* (2015), doi: <http://dx.doi.org/10.1016/j.bmc.2015.05.051>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.





Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier.com

Benzimidazole Derivatives as Potential Dual Inhibitors for PARP-1 and DHODH

Iskandar Abdullah^{a*}, Chee Chin Fei^{a,b,c}, Lee Yean Kee^a, Siva Sanjeeva Rao Thunuguntla^c, K Satish Reddy^c, Kavitha Nellore^c, Thomas Antony^{c*}, Jitender Verma^c, Kong Wai Mun^b, Shatrah Othman^{a,d}, Hosahalli Subramanya^c, Noorsaadah Abd Rahman^{a1*}

^aDrug Design and Development Research Group, Department of Chemistry, Faculty of Science, University of Malaya, Malaysia.

^bAurigene Discovery Technologies (Malaysia) Sdn. Bhd.

^cAurigene Discovery Technologies (India) Ltd.

^dDepartment of Molecular Medicine, Faculty of Medicine, University of Malaya, Malaysia.

¹School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.

ARTICLE INFO

ABSTRACT

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

Poly(ADP-ribose) polymerase

PARP

PARP-1

Dihydroorotate dehydrogenase

DHODH

Benzimidazole

Poly (ADP-ribose) polymerases (PARPs) play diverse roles in various cellular processes that involve DNA repair and programmed cell death. Amongst these polymerases is PARP-1 which is the key DNA damage-sensing enzyme that acts as an initiator for the DNA repair mechanism. Dihydroorotate dehydrogenase (DHODH) is an enzyme in the pyrimidine biosynthetic pathway which is an important target for anti-hyperproliferative and anti-inflammatory drug design. Since these enzymes share a common role in the DNA replication and repair mechanisms, it may be beneficial to target both PARP-1 and DHODH in attempts to design new anti-cancer agents.

Benzimidazole derivatives have shown a wide variety of pharmacological activities including PARP and DHODH inhibition. We hereby report the design, synthesis and bioactivities of a series of benzimidazole derivatives as inhibitors of both the PARP-1 and DHODH enzymes.

2009 Elsevier Ltd. All rights reserved.

1. Introduction

Poly (ADP-ribose) polymerases (PARPs) comprise 18 putative family members of the nuclear enzymes that have significant roles in multifunctional cellular processes, including detection and repair of damaged DNA and RNA (Ame, Spenlehauer, & de Murcia, 2004). PARP-1, PARP-2 and PARP-3 are the best studied members of this family of enzymes due to their role in DNA repair (Sousa *et al.*, 2012). Other distinct biochemical activities of PARP-1 are epigenetic chromatic modifications, genomic stability regulations (Caiafa, Guastafierro, & Zampieri, 2009; Quénet, El Ramy, Schreiber, & Dantzer, 2009), replication and transcription of DNA (Messner & Hottiger, 2011) and distinctive cell death formation known as parthanatos (David, Andrabi, Dawson, & Dawson, 2009; Fatokun, Dawson, & Dawson, 2014). PARP-1 is known to be the trigger point in the DNA repair mechanism for single strand breaks where it acts as the DNA damage-sensing enzyme. In response to DNA damage that may have occurred due to radiation or chemotherapeutic agents, PARP-1 initiates its repair process by binding to the damaged site and catalyzing the synthesis of long, branched poly (ADP-ribose) chains using nicotinamide adenine dinucleotide (NAD⁺) as the substrate. These actions of PARP-1 result in the resistance that frequently develops after cancer therapy. Hence inhibition of the PARP-1 enzyme is believed to enhance sensitivity towards radiotherapy and certain kinds of DNA targeting cancer chemotherapies (Kummar *et al.*, 2012).

To date, a significant number of potent PARP-1 inhibitors have been reported accentuating the role of PARP-1. Inhibition of PARP in homologous recombination (HR) deficient tumor cells have also exclusively explained the crucial role of PARP-1 in DNA repair (De Lorenzo, Patel, Hurley, & Kaufmann, 2013; Underhill, Toulmonde, & Bonnefoi, 2010). These inhibitors generally bind to the nicotinamide binding site of the PARP-1 catalytic domain, thus inhibiting automodification and subsequent release of the enzyme from the site of DNA damage as well as preventing the access of other repair proteins to the site of DNA damage. The binding of these inhibitors mimics the binding mode of nicotinamide towards PARP-1 with key interactions to Ser243 (C=O to O-H Ser) and Gly202 (C=O to N-H Gly and N-H to C=O Gly) through hydrogen-bonding and – stacking with Tyr246, which is approximately coplanar with the benzimidazole moiety of the ligand (White *et al.*, 2000). In addition, Griffin and co-workers reported an intramolecular hydrogen bond between the carboxamide hydrogen on C2 of the indole ring to the nitrogen in the indole ring. This intramolecular H-bond resulted in a pseudo-6-membered ring, creating a rigid 6:6:5 tricyclic system which improved its potency (Griffin *et al.*, 1998; Suto, Turner, Arundel-Suto, Werbel, & Sebolt-Leopold, 1991). A water molecule also plays a crucial role at the active site by interacting with the catalytically important carboxylate group of Glu327 which forms a hydrogen bond with the NH indole of benzimidazole of the ligand (White *et al.*, 2000; White *et al.*, 2004).

Inhibition of pyrimidine biosynthesis has been shown to have an efficacious anti-proliferative effect on cells that are dividing rapidly (Evans & Guy, 2004). Mitochondrial enzyme, dihydroorotate dehydrogenase (DHODH) catalyzes the fourth step in the *de novo* biosynthetic pathway of pyrimidines, converting dihydroorotate to orotate by oxidative reaction, with flavin mononucleotide (FMN) and ubiquinone (CoQ) acting as


co-factors (Evans & Guy, 2004). This enzyme has been identified as a therapeutic target for treatment of cancer (Chen, Ruben, & Dexter, 1986; Dexter *et al.*, 1985), as well as several autoimmune disorders such as rheumatoid arthritis and multiple sclerosis (Herrmann, Schleyerbach, & Kirschbaum, 2000). Inhibition of enzymatic activities has been reported on *h*DHODH and *Pf*DHODH by x-ray crystallographic studies with known inhibitors such as leflunomide, teriflunomide (the active metabolite of leflunomide) and brequinar. These inhibitors are positioned in the suggested ubiquinone binding site where polar and hydrophobic residues contribute to the binding. The carboxylic acid group from the inhibitors shows good hydrogen-bonding interactions with the guanidinyll moiety of Arg136 and an additional hydrogen bonding interaction to the side chain of Glu47.

Targeting both PARP-1 and DHODH for anti-cancer therapy would certainly be beneficial as these enzymes share a common role in the DNA replication and repair mechanisms which are involved in the hyper-proliferation of cancer cells. Since benzimidazole-containing compounds have been reported to show good pharmacological activity against these targets (Bonn, 2002; Calabrese *et al.*, 2004; Refaat, 2010), we have chosen them as lead structures in the search for dual PARP-1/DHODH inhibitors described in this study.

2. Results and Discussion

2.1 Chemistry


Numerous reports on benzimidazole ring system construction have been published (Barkalow *et al.*, 2007; Penning *et al.*, 2009; Penning *et al.*, 2008).



Scheme 1. Side chain preparation from phenyl ester 1

We started off with the preparation of methyl ester **1** with different functional groups placed at the *ortho* (R₃), *meta* (R₄) and *para* (R₅) positions of the phenyl ring moiety to be connected at position 2 of the benzimidazole core as shown in Scheme 1. Saponification of **1** led to carboxylic acids **2a-z** (supporting information). Two different routes were employed to prepare the benzimidazole compounds (Scheme 2). Route 1 involved coupling of diamine **3** using standard 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) in dimethylformamide and the presence of N,N-diisopropylethylamine (DiPEA) as base (Zhu *et al.*, 2012) for the formation of **5**. Subsequent thermal cyclization of **5** in AcOH gave intermediate **6**. Saponification of ester **6** with LiOH provided carboxylic acid derivatives **7a-g** (Table 1), which were then converted to the corresponding carboxamide benzimidazole derivatives **9a-i**, **10a-i** and **11a-j** with hydroxybenzotriazole (HOBt) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI).

Alternatively, **9a-i**, **10a-i** and **11a-j** (Table 2) could be prepared via Route 2. Reacting 2,3-diaminobenzamide (**4**) with **2a-z** in the presence of 1,1'-carbonyldiimidazole (CDI) in pyridine and dimethylformamide (DMF) (1:1 v/v) gave amide **8** which could be cyclized to benzimidazole **9**, **10** and **11** by refluxing in AcOH as reported by Penning and co-workers (Penning *et al.*, 2009).




Scheme 2. General strategy for the synthesis of benzimidazole carboxamide and carboxylic acid derivatives.

Table 1. Chemical structure of benzimidazole carboxylic acid derivatives synthesized via Scheme 2.

Entry	Compound
7a	
7b	
7c	
7d	
7e	
7f	

7g



2.2. Pharmacological Evaluation

2.2.1. Poly (ADP-ribose) Polymerase (PARP) Colorimetric Assay

The inhibitory effect of compounds **7a-g**, **9a-i**, **10a-i** and **11a-j** on PARP-1 activity was measured using an HT Universal Colorimetric PARP assay kit (Trevigen, Gaithersburg, MD, USA). With slight modification, the assays were carried out by quantifying the incorporation of biotinylated poly (ADP-ribose) onto histone proteins in 96-well plate. In brief, the experiment began with pre-incubating 10 μ l of PARP-1 enzyme (0.25 U) with 15 μ l of tested compounds in rehydrated histone-coated wells followed by addition of 25 μ l of PARP cocktail mixture containing 2 μ l of 10x PARP Cocktail, 2 μ l of 10x activated DNA and 21 μ l of 1x PARP buffer into the wells. After 60 min of incubation, the wells were washed twice with 1x PBS + 0.1% Triton X-100 followed by 1x PBS. 50 μ l of 1x Strep-HRP was then added and incubated for 60 min. The wells were washed again as in the previous step. 50 μ l of pre-warmed TACS-Sapphire substrate was added and the mixture was incubated for 15 min in the dark. The reactions were terminated with 50 μ l 0.2 M HCl. The absorbance reading at 450 nm was measured using a VICTOR X5 2030 Multilabel Reader (Perkin-Elmer, Waltham, MA, USA). IC₅₀ values were determined by fitting the activity data at different concentrations of the compound to a sigmoidal dose-response curve using GraphPad Prism software version 6.00.


2.2.2. Dihydroorotate Dehydrogenase (DHODH) Enzymatic Assay

Compounds **7a-g**, **9a-i**, **10a-i** and **11a-j** were evaluated for their potency to inhibit DHODH in a coupled enzymatic spectrophotometric assay. The assay is based on the decrease in absorbance at 610 nm resulting from the oxidation of L-dihydroorotic acid (L-DHO) facilitated by the reduction of 2,6-dichloroindophenol (DCIP) and decylubiquinone (DUQ) (Baldwin *et al.*, 2005). The decrease in absorbance at 610 nm is proportional to the reduction of DCIP. The assay buffer was 50 mM TrisHCl, 150 mM KCl and 0.8% Triton, pH 8.0. A 100 μ l reaction mixture was used in 96-well plates at room temperature. A mixture of 82 μ l of enzyme (25 ng) in buffer and 5 μ l of test compounds were pre-incubated for 30 min and the reaction was started by adding 13 μ l of substrate mixture (20 mM of L-DHO, 2 mM of DUQ and 2 mM of DCIP). The final concentration of DMSO used was 1%. The absorbance of each well was measured after 20 min of the reaction at 610 nm using a VICTOR X5 Multilabel Reader (Perkin-Elmer) every 10 min for 1 hour. IC₅₀ values were determined from the dose response plot using GraphPad Prism software version 6.00.

The preliminary activity for both the PARP and DHODH assays was measured at 10 μ M concentration of the synthesized compounds (**7a-g**, **9a-i**, **10a-i** and **11a-j**) along with veliparib and beprinarib as reference inhibitors (Table 3).

Table 2. Chemical structure of benzimidazole carboxamide derivatives synthesized via Scheme 2.

Entry	Product	Entry	Product	Entry	Product
9a ^a		10a		11a	
9b		10b		11b	
Continue from Table 2					
9c ^b		10c		11c	
9d		10d		11d	
9e ^b		10e ^a		11e	
9f		10f		11f	
9g		10g		11g	
9h		10h		11h	
9i ^a		10i		11i	
				11j	

^aCompounds reported by Tong *et al.* (Tong *et al.*, 2009).^bCompounds reported by White *et al.* (White *et al.*, 2000).**Table 3.** PARP-1 and DHODH inhibition by benzimidazole derivatives. The activity is expressed as percent inhibition at 10 μM or IC_{50} values.

Entry	R ₁	R ₂	R ₃	R ₄	R ₅	PARP-1		DHODH	
						IC ₅₀ (μM) / % inhibition at 10 μM		IC ₅₀ (μM) / % inhibition at 10 μM	

Veliparib (ABT-888)						0.005	-
Brequinar						-	0.012
9a	NH ₂	H	H	H		0.71	9.80
9b	NH ₂	CH ₃	H	H		28%	7.80
9c	NH ₂	H	H	H		N.A	N.A
9d	NH ₂	CH ₃	H	H		N.A	N.A
9e	NH ₂	H	H	H		N.A	N.A
9f	NH ₂	CH ₃	H	H		N.A	N.A
9g	NH ₂	CH ₃	H	H		N.A	N.A
9h	NH ₂	H	H	H		0.032	20%
9i	NH ₂	H	H	H		0.022	19%

Continue from **Table 3**

10a	NH ₂	H	H	H		0.029	28%
10b	NH ₂	CH ₃	H	H		N.A	50%
10c	NH ₂	H	H	H		0.012	N.A
10d	NH ₂	CH ₃	H	H		17%	37%
10e	NH ₂	H	H	H		0.083	28%
10f	NH ₂	H	H	H		0.14	51%
10g	NH ₂	H	H	H		0.46	42%
10h	NH ₂	H	H	H		16%	56%
10i	NH ₂	H	H	H		0.31	20%
11a	NH ₂	CH ₃	H	H		N.A	N.A
11b	NH ₂	H	H	H		0.049	40%
11c	NH ₂	H	H	H		0.061	55%
11d	NH ₂	CH ₃	H	H		2.28	N.A
11e	NH ₂	H	H	H		0.72	31%
11f	NH ₂	F	F	H		0.084	48%
11g	NH ₂	F	H	H		1.72	N.A
11h	NH ₂	F	F	H		1.28	38%
11i	NH ₂	F	F	H		0.98	23%

11j	NH ₂	F	H	H		5.96	N.A
7a	OH	CH ₃	H	H		N.A	0.21
7b	OH	CH ₃	H	H		N.A	1.38
7c	OH	CH ₃	H	H		N.A	32%
7d	OH	CH ₃	H	H		10.63	0.30

Continue from **Table 3**

7e	OH	CH ₃	H	H		N.A	0.028
7f	OH	CH ₃	H	H		44%	0.013
7g	OH	CH ₃	H	NHAc		N.A	47%

*N.A = Not active (less than 15% inhibition @ 10 μ M)

2.3. Structure-activity relationship (SAR) studies

In this work, we designed and synthesized diversified compounds (as shown in Table 3) by substituting various electron-donating and electron-withdrawing groups into the benzimidazole scaffold and evaluated their biological activities for the two targets, PARP-1 and DHODH. The compounds were docked into PARP-1 and DHODH, and their interactions with the active site residues were analyzed in order to rationalize their potencies in the two targets. Compound **11** (Figure 1) has been reported by Thunuguntla's group to inhibit DHODH (Thunuguntla *et al.*, 2010) with IC₅₀ of 0.75 μ M. Replacing the carboxylic acid substituent at the C4 position of the benzimidazole ring in this compound with an amide functionality (**9a**) gave improved activity against PARP-1 (IC₅₀ = 0.71 μ M), but at the same time the DHODH potency was reduced by several folds (IC₅₀ = 9.80 μ M.). Introduction of the amide group probably would have reduced the strength of H-bonding in this crucial region of the DHODH active site, which appears to prefer a purely acceptor moiety (like the COOH group which gets deprotonated at pH 7.4) to form H-bonds with the donor groups of Arg136 & Gln47, and a water-mediated H-bond with Thr360 (Figure 1A). This observation indicated that the COOH group at C4 position favors DHODH activity, while the CONH₂ substituent favors PARP-1 activity (by gaining polar contacts with the donor and acceptor groups of Ser243 and Gly202 as shown in Figure 1B). Incorporating a CH₃ group at the R₂ position of the benzimidazole ring (**9b**) proved detrimental for PARP-1 activity, but it slightly improved the DHODH potency (Figure 2). This might be due to the availability of enough space to accommodate a methyl group at this particular site of the DHODH pocket, in comparison to that in the PARP-1 active site where the same group could not be endured well.




Figure 1. Docking modes showing the interactions of compounds **11** (A) and **9a** (B) in DHODH (pdb ID: 4IGH) and PARP-1 (pdb ID: 4HHZ) respectively.




Figure 2. Structure and biochemical activity of compounds **9a** and **9b**.

Compounds **9c-g**, with functional groups other than a phenyl ring at the *para* position (R₅) were found to be completely inactive for both targets. Substituting a strongly electron-donating methoxy group at R₅ position (**9c** and **9d**), produced a devastating effect on the activity. Another approach was then carried out by substituting strong electron-withdrawing groups at this position such as -CF₃ (**9e** and **9f**) and -CN (**9g**), but these also proved to be inactive. These observations indicated that instead of small electron donating or withdrawing groups, a relatively bulkier system (e.g. in the form of a second phenyl ring) is required to sufficiently occupy the space available around this position in both PARP-1 and DHODH enzymes.

Further investigations were performed on the second phenyl ring in order to study the effect of substituting various functional groups at its *ortho*, *meta* and *para* positions. Incorporation of an acetamide group (NHAc) at the *ortho* (**10f**) and *meta* (**10g**) positions showed significant improvement especially in PARP-1 potency, but *para* substitution (**10h**) resulted in the loss of activity compared to the parent compound **9a**. These *o*- and *m*-acetamide substitutions showed H-bonding interactions with Arg217 (water-mediated) and Asp105 respectively, but the *p*-substitution failed to fetch any such interaction in PARP-1. In case of DHODH, the *o*- (**10f**) and *p*- (**10h**) acetamide substituted

compounds did show H-bonding with Tyr38 and Leu67 respectively, but they only seemed to result in around 50% inhibition of the activity at 10 μM concentration (Compound **10g** also demonstrated 45% inhibition of the DHODH activity at a relatively lower concentration of 1 μM). The interactions between compound **10g** and the active site residues of DHODH and PARP-1 is shown in Figure 3




Figure 3. Docking modes showing the interactions of compound **10g** in DHODH (A, pdb ID: 4IGH) and PARP-1 (B, pdb ID: 4HHZ) respectively.

Substituting pyrrolidinyl methanone at the *para* position of the second phenyl ring as in the compounds **10c** and **10i** showed comparable potency in PARP-1 but poor activity in DHODH enzyme. As observed with compound **9b**, methyl substitution at the R_2 position for compounds **10d** and **11a** resulted in diminished activities, particularly for PARP-1 enzyme. When pyrrolidinyl methanone was substituted at position 3 of the pyridine ring as depicted by compounds **10a** and **10b**, a reduction in the activity was observed against both PARP-1 and DHODH as compared to the parent compound **9i**. Compound **10b** showed poor activity in PARP-1 probably due to the presence of the unfavorable $-\text{CH}_3$ group at the R_2 position. It is noteworthy that in all these analogs, the pyrrolidinyl methanone moiety could not gain any polar contact in the active site of both PARP-1 and DHODH. Increasing the chain length at *para* position of the second phenyl ring of the benzimidazole in compound **11d** did not result in good inhibitory activities. Compound **11e**, with one carbon atom less than **11d** however, exhibited reasonable activity. In both these compounds, the piperidinyl nitrogen got protonated at pH 7.4 and entered into H-bonding with Ile218 and Tyr38 in PARP-1 and DHODH respectively.

Substituting the R_3 position of the benzimidazole scaffold with a hetero-aromatic moiety and removing the methyl substituent from the R_2 position dramatically improved the PARP-1 activity as exhibited by compound **9i** ($\text{IC}_{50} = 0.022 \mu\text{M}$). A slight decrease in activity was observed with electron donating groups attached to the hetero-aromatic moiety, for example, in compounds **9h** ($-\text{NH}_2$, $\text{IC}_{50} = 0.032 \mu\text{M}$) and **11b** ($-\text{NHCOCH}_3$, $\text{IC}_{50} = 0.049 \mu\text{M}$). Compound **10e** with a 2-pyrinyl moiety at R_5 position showed a drop in activity in PARP-1 with IC_{50} of 0.083 μM . The compounds **9h** and **11b** with polar groups (NH_2 and NHAc respectively) towards the solvent exposed region could not fetch any polar interaction in PARP-1 active site. Though the pyridyl nitrogen (in most of the acetamide analogs) and the $-\text{NHCOCH}_3$ group in **11b** did form H-bond with Tyr38 and Leu67 respectively in the DHODH pocket, but they failed to enhance the potency. In addition, a 3-fold drop in PARP-1 activity was observed with compound **11c** having a methyl-pyrrolidine moiety at position 3 of the pyridine ring ($\text{IC}_{50} = 0.061 \mu\text{M}$), but at the same time there is an increase in the DHODH activity to 55% at 10 μM concentration. However, the protonated nitrogen of the methyl-pyrrolidine group in this compound could not gain any polar contact in both the PARP-1 and DHODH enzymes.

The effects of fluoro and cyclopropane substitutions as bioisosteres were also investigated while maintaining the carboxamide group at the R_4 position of the benzimidazole

scaffold. The only compound which demonstrated modest PARP-1 and DHODH dual activities was **11f** with fluorine substituted at R_3 and *meta* position of the second phenyl ring, in addition of the cyclopropanecarboxamide group at the *para* position. However, other compounds in the same class, **11g**, **11h**, **11i** and **11j**, failed to exhibit any improvement in the dual activity. Compared to the methyl group, fluoro was well tolerated at R_2 position and resulted in improved PARP-1 activity. The cyclopropanecarboxamide group in most of these analogs formed H-bonding with Tyr49 and Leu67 in PARP-1 and DHODH respectively.

Since it has been reported that the $-\text{COOH}$ group at the R_4 position is favorable for DHODH activity (Batt *et al.*, 1995; Batt *et al.*, 1998; Munier-Lehmann, Vidalain, Tangy, & Janin, 2013), we proceeded to synthesize seven benzimidazole carboxylic acid derivatives (Table 1). All these compounds have a methyl group at R_2 position, along with varied substitutions primarily on the second phenyl ring. Compound **7a** with an acetamide group at the *para* position of the second phenyl ring showed reasonably good DHODH activity ($\text{IC}_{50} = 0.21 \mu\text{M}$), compared to the *ortho* (**7c**) and *meta* (**7b**) substituted analogs. Similarly, compounds **7d**, **7e**, and **7f**, with a much bulkier substitution at the *para* position of the second phenyl ring displayed modest DHODH inhibitory activities ($\text{IC}_{50} = 0.30 \mu\text{M}$, 0.028 μM , and 0.013 μM respectively). However, all the compounds shown in Table 1 had weak activity for PARP-1 except for compound **7f** which exhibited 44% inhibition at 10 μM concentration. The diminished PARP-1 activity of all these compounds may be attributed partly to the detrimental effect of methyl group at R_2 position, as well as to the absence of the favorable carboxamide moiety at R_4 position of the benzimidazole moiety. A summary of our SAR findings with respect to PARP-1 and DHODH dual inhibition is shown in Figure 4.




Figure 4. Summary of the SAR points for possible dual inhibition of DHODH and PARP-1 enzymes.

3. Conclusion

We have studied various benzimidazole derivatives as prospective inhibitors of both PARP-1 and DHODH enzymes. All the compounds have been synthesized in good yields. Several compounds, namely **7f**, **10g**, **11c** and **11f** showed dual potencies, albeit with relatively lower activity for both the targets. These compounds, however, can be considered for further study to understand the binding mechanisms and enhance their potential as dual inhibitors of PARP-1 and DHODH.

4. Experimental

4.1. Modeling

4.1.1 Ligand and Protein Preparation

The 2D structures of the ligands were sketched using ChemBioDraw Ultra 12.0 program and then converted into 3D format with the *LigPrep* utility of Schrödinger Software Suite 2014-1. Similarly the protein-ligand complexes, obtained from the Protein Data Bank (PDB ID: 4IGH for DHODH and 4HHZ for PARP-1) were prepared using the *Protein Preparation Wizard* utility of the software. Hydrogen atoms were added, bond orders assigned, missing side-chains filled, and water molecules outside the active site deleted, followed by restrained minimization to relieve the strain and steric clashes in the protein-ligand complexes.

4.1.2 Receptor-grid generation

Using the *Glide* module of the Schrödinger Software Suite, the active site was defined by constructing a receptor grid spanning amino acid residues within a distance of around 10 Å from the co-crystallized ligand in the protein complexes. Some key hydrogen-bonding constraints (involving residues such as Gln47 & Arg136 in DHODH and Gly202 & Ser243 in PARP-1) were also defined while generating the receptor grid, to be employed in protein-ligand docking.

4.1.3 Protein-ligand docking

The prepared ligands (in sdf format) and protein structures (as receptor grids) were supplied as input files to the *Glide* module of the software for docking. During *Glide* docking, extra precision (XP) mode was employed. The protein was kept rigid, while ligands were given full flexibility in addition to sampling of nitrogen inversions and ring conformations. However the amide torsions were restricted to the trans-conformation only. Other parameters included adding *Epik* state penalties to docking scores, rewarding intramolecular hydrogen bonds, and enhancing planarity of the conjugated pi groups. The docking protocol was set to report at least 10 poses per ligand, which were viewed and analyzed within the protein active site for desired interactions using the *Maestro* viewer of the Schrödinger Software Suite.

4.2. Chemistry

Chemicals and reagents were either purchased from Merck, Sigma-Aldrich or provided by Aurigene Discovery Technologies Limited and used without further purification. NMR spectra were recorded on JEOL Lambda 400 and ECA 400. Thin layer chromatography (TLC) were carried out by using aluminium sheets TLC silica 60 F₂₅₄ and flash column chromatography used were silica gel (40-60µm) purchased from Merck. Anhydrous tetrahydrofuran (THF) used were purified from PureSolv solvent purification system and dichloromethane (CH₂Cl₂) were distilled from CaH₂ prior to use. Melting point were measured with Stuart Melting 30 (SMP 30) apparatus. Semi-preparative HPLC was performed on Waters HPLC Binary PUMP 1525, Waters Photodiode Array Detector 2998 with Merck Chromolith@ Performance Reverse-phase C-18 column (100-4.6mm). LC/MS was run on Agilent 1200 Series / Agilent Technologies 6530 Q-TOF (ESI) with Agilent Zorbax C-18 column.

4.2.1. General procedure for synthesis of 5

To a round bottom flask equipped with a magnetic stir bar was added diamine benzoate (**3**; R₂ = CH₃; F) (1 mmol), carboxylic

acid **2a-z** (1 mmol), HATU (1.3 mmol) and dissolved in DMF (6 ml) stirred under N₂ gas. DiPEA (2 ml) was then added to the mixture and reaction mixture was left to stir for 3 hours. Water (100 ml) was added to the reaction mixture, filtered and dried to afford **5** which was used without further purification

4.2.2. General procedure for synthesis of 6

Compound **5** was dissolved in acetic acid (10 ml/mmol) and refluxed at 130°C until reaction is fully completed under TLC analysis monitoring. Flash column chromatography with EtOAc:Hex (3:1 v/v) elution yielded purified compound **6**.

4.2.3. General procedure for synthesis of 7

Compound **6** was dissolved in mixture of MeOH:THF (1:1 v/v) followed by the addition of LiOH.H₂O (3-5 eq) per mol and the reaction mixture was allowed to stir overnight. Upon reaction completion, solvents were removed *in vacuo*. The resulted aqueous mixture pH was adjusted to 2 with 10% HCl to obtain the desired product **7** which was filtered and dried and used without further purification

4.2.4. General procedure for synthesis of 8

To a solution of DMF:pyridine (1:1 v/v) was added compound **2a-z** (0.9 mmol) and 1,1'-carbonyldiimidazole (CDI) (0.9 mmol) stirred at 60°C under N₂ gas atmosphere for 3 hours. After the reaction mixture was cooled down to room temperature, 2,3-diaminobenzamide **4** (1 mmol) was added and left to stir overnight until the completion of the reaction as monitored by TLC analysis. Water (100 ml) was added and the resulting product **8** was filtered and dried without further purification.

4.2.5 General procedure for synthesis of 9, 10 and 11

4.2.5.1 From compound 7

To a solution of DMF (6 ml) was added EDCl.HCl (2 mmol), HOBt (2 mmol), NH₄Cl (5 mmol), compound **7** (1 mmol) followed by DiPEA (1 ml) and was left to stir overnight until reaction was completed judged by TLC analysis. Water (100 ml) was added to the reaction mixture which the resulting product was filtered and dried to afford compound **9, 10 and 11**.

4.2.5.2. From compound 8

Compound **8** was dissolved in acetic acid (AcOH) (10 ml/mmol) and refluxed at 130°C until reaction was fully completed under TLC analysis monitoring. Flash column chromatography with EtOAc:Hex (3:1 v/v) elution yielded purified compound **9, 10 and 11**.

4.2.6. 2-(4'-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7a). ¹H NMR (400MHz, DMSO-*d*₆): δ 10.28 (s, NH), 8.33 (d, *J*=8.3, 2H), 7.91 (d, *J*=8.0, 2H), 7.83 (s, 1H), 7.81 (s, 1H), 7.75 (d, *J*=9.0, 2H), 7.72 (d, *J*=8.8, 2H), 2.50 (s, 3H), 2.06 (s, 3H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 169.10, 166.12, 151.38, 143.58, 139.96, 135.99, 134.90, 133.14, 131.05, 129.69, 128.22, 127.49, 126.71, 123.07, 119.71, 119.44, 117.08, 24.23, 21.12. HRMS (ESI) calculated for C₂₅H₁₉N₃O₃ (M+H)⁺: 386.1504, found 386.1499.

4.2.7. 2-(3'-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7b). ¹H NMR (270MHz, DMSO-*d*₆): δ 10.08 (s, NH), 8.37 (d, *J*=8.1, 2H), 7.97 (s, 1H), 7.76 (d, *J*=8.4, 2H), 7.70 (s, 1H), 7.65 (s, 1H), 7.60 (bs, 1H), 7.41 (s, 1H), 7.39 (s, 1H), 2.46 (s, 3H), 2.07 (s, 3H). ¹³C NMR (67MHz, DMSO-*d*₆): δ 168.67, 166.83, 152.52, 141.74, 140.04,

139.82, 129.53, 128.60, 128.12, 126.91, 125.80, 121.57, 118.67, 117.32, 24.12, 21.02. HRMS (ESI) calculated for $C_{23}H_{19}N_3O_3$ (M+H)⁺: 386.1504, found 386.1502.

4.2.8. 2-(2'-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7c). ¹H NMR (270MHz, CD₃OD): δ 8.03 (d, *J*=8.3, 2H), 7.84 (s, 1H), 7.53 (d, *J*=8.3, 1H), 7.40 (d, *J*=8.3, 2H), 7.38 (d, *J*=5.9, 1H), 7.30-7.21 (m, 3H), 2.33 (s, 3H), 1.88 (s, 3H). ¹³C NMR (67MHz, CD₃OD): δ 172.44, 167.62, 154.55, 145.16, 142.97, 138.17, 135.47, 133.25, 131.39, 130.50, 129.48, 128.58, 128.52, 128.46, 127.96, 127.44, 124.14, 115.25, 22.92, 21.29. HRMS (ESI) calculated for $C_{23}H_{19}N_3O_3$ (M+H)⁺: 386.1504, found 386.1510.

4.2.9. 2-(4'-(2-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7d). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.66 (s, NH), 8.40 (d, *J*=8.5, 2H), 7.96 (d, *J*=7.9, 2H), 7.89 (bs, 2H), 7.80 (d, *J*=8.5, 2H), 7.47 (d, *J*=7.3, 1H), 7.43 (d, *J*=7.9, 1H), 7.30 (t, *J*=7.9, 1H), 7.20 (t, *J*=7.3, 1H), 7.12 (d, *J*=8.5, 2H), 5.16 (s, 2H), 2.54 (s, 3H), 2.07 (s, 3H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 168.71, 165.65, 158.94, 150.77, 144.10, 135.75, 130.88, 130.76, 130.04, 129.97, 129.49, 128.71, 128.33, 128.02, 126.44, 125.42, 125.30, 121.20, 118.51, 117.25, 115.50, 66.24, 23.31, 20.87. HRMS (ESI) calculated for $C_{30}H_{25}N_3O_4$ (M+H)⁺: 492.1923, found 492.1929.

4.3.0. 2-(4'-(3-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7e). ¹H NMR (400MHz, DMSO-*d*₆): δ 10.26 (s, NH), 8.40 (d, *J*=8.3, 2H), 7.89 (d, *J*=8.3, 2H), 7.84 (s, 1H), 7.83 (s, 1H), 7.78 (s, 1H), 7.73 (d, *J*=8.5, 2H), 7.60 (d, *J*=8.0, 1H), 7.31 (t, *J*=7.8, 1H), 7.13 (d, *J*=10.2, 1H), 7.10 (d, *J*=8.8, 2H), 5.12 (s, 2H), 2.51 (s, CH₃), 2.09 (s, CH₃). ¹³C NMR (100MHz, DMSO-*d*₆): δ 168.66, 165.72, 158.89, 150.65, 143.78, 139.67, 137.47, 135.24, 134.37, 130.83, 129.99, 129.80, 128.86, 128.41, 128.23, 126.34, 122.19, 121.55, 118.62, 118.08, 117.09, 115.46, 115.42, 69.42, 24.12, 20.96. HRMS (ESI) calculated for $C_{30}H_{25}N_3O_4$ (M+H)⁺: 492.1923, found 492.1922.

4.3.1. 2-(4'-(4-acetamidobenzyl)oxy)-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7f). ¹H NMR (400MHz, DMSO-*d*₆): δ 10.30 (s, NH), 8.34 (d, *J*=8.5, 2H), 7.88 (d, *J*=8.5, 2H), 7.78 (bs, 2H), 7.75 (d, *J*=8.8, 2H), 7.60 (d, *J*=8.5, 2H), 7.38 (d, *J*=8.5, 2H), 7.12 (d, *J*=8.8, 2H), 5.09 (s, 2H), 2.03 (s, CH₃). ¹³C NMR (100MHz, DMSO-*d*₆): δ 168.41, 166.14, 158.77, 151.65, 143.06, 139.09, 133.69, 131.29, 131.14, 129.11, 128.48, 128.14, 127.34, 126.37, 124.12, 120.01, 118.95, 116.60, 115.50, 69.18, 24.11, 20.91. HRMS (ESI) calculated for $C_{30}H_{25}N_3O_4$ (M+H)⁺: 492.1923, found 492.1928.

4.3.2. 2-(2-acetamido-[1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxylic acid (7g). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.52 (s, NH), 8.40 (s, 1H), 8.22 (d, *J*=7.8, 1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.52 (d, *J*=8.1, 1H), 7.49-7.46 (m, 5H), 1.95 (s, 3H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 169.06, 166.51, 151.76, 139.21, 138.29, 135.32, 132.22, 130.79, 128.66, 128.55, 127.73, 127.55, 127.05, 126.43, 125.49, 116.10, 22.97, 20.98. HRMS (ESI) calculated for $C_{23}H_{19}N_3O_3$ (M+H)⁺: 386.1504, found 386.1505.

4.3.3. 2-([1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (9a). Compound reported by (Tong *et al.*, 2009).

4.3.4. 2-([1,1'-biphenyl]-4-yl)-6-methyl-1H-benzimidazole-4-carboxamide (9b). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.29 (s, CONH₂), 9.34 (s, NH), 8.31 (d, *J*=7.1, 2H), 7.91 (d, *J*=8.1, 1H), 7.79 (d, *J*=7.8, 2H), 7.72 (s, 1H), 7.54 (s, 1H), 7.51 (t, *J*=7.8, 2H), 7.43 (t, *J*=7.3, 1H). ¹³C NMR (100MHz, DMSO-*d*₆): δ

166.33, 151.19, 141.89, 139.83, 139.18, 135.76, 132.02, 129.14, 128.23, 128.11, 127.37, 127.33, 126.80, 124.39, 121.87, 114.82, 21.34. HRMS (ESI) calculated for $C_{21}H_{17}N_3O$ (M+H)⁺: 328.1449, found 328.1461.

4.3.5. 2-(4-methoxyphenyl)-1H-benzimidazole-4-carboxamide (9c). Compound reported by (White *et al.*, 2000).

4.3.6. 2-(4-methoxyphenyl)-6-methyl-1H-benzimidazole-4-carboxamide (9d). ¹H NMR (270MHz, DMSO-*d*₆): δ 12.99 (s, CONH₂), 9.28 (s, NH), 8.09 (d, *J*=8.9, 2H), 7.61 (s, 1H), 7.41 (s, 1H), 7.07 (d, *J*=8.9, 2H), 3.79 (s, 3H), 2.41 (s, 3H). ¹³C NMR (67MHz, DMSO-*d*₆): δ 166.33, 161.03, 151.59, 139.84, 135.63, 131.35, 128.39, 123.97, 121.72, 121.53, 114.52, 114.47, 55.41, 21.25. HRMS (ESI) calculated for $C_{16}H_{15}N_3O_2$ (M+H)⁺: 282.1242, found 282.1239.

4.3.7. 2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-4-carboxamide (9e). Compound reported by (White *et al.*, 2000).

4.3.8. 6-methyl-2-(4-(trifluoromethyl)phenyl)-1H-benzimidazole-4-carboxamide (9f). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.52 (bs, CONH₂), 9.24 (s, NH), 8.44 (d, *J*=8.1, 2H), 7.96 (d, *J*=8.1, 2H), 7.74 (s, 1H), 7.57 (s, 1H), 2.47 (s, 3H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 166.09, 149.81, 139.51, 135.78, 133.10, 132.54, 130.16, 129.84, 128.14, 127.42, 126.00, 122.72, 122.19, 115.19, 21.25. HRMS (ESI) calculated for $C_{16}H_{12}N_3F_3O$ (M+H)⁺: 320.1010, found 320.1009.

4.3.9. 2-(4-cyanophenyl)-6-methyl-1H-benzimidazole-4-carboxamide (9g). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.45 (bs, CONH₂), 9.29 (s, NH), 8.31 (d, *J*=9.7, 2H), 8.06 (d, *J*=7.3, 2H), 7.72 (d, *J*=1.8, 1H), 7.55 (d, *J*=1.7, 1H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 167.81, 166.67, 151.10, 140.12, 136.18, 135.99, 132.81, 132.15, 128.72, 127.03, 125.12, 122.48, 115.45, 21.77. HRMS (ESI) calculated for $C_{16}H_{12}N_4O$ (M+H)⁺: 277.1089, found 277.1092.

4.4.0. 2-(4-(6-aminopyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (9h). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.39 (s, CONH₂), 9.39 (s, NH), 8.39 (s, 1H), 8.27 (d, *J*=8.3, 2H), 7.88-7.79 (m, 4H), 7.74 (d, *J*=8.3, 1H), 7.35 (t, *J*=7.6, 1H), 6.58 (d, *J*=8.7, 1H), 6.28 (s, NH₂). ¹³C NMR (100MHz, DMSO-*d*₆): δ 166.21, 159.46, 151.83, 145.83, 141.58, 140.06, 135.48, 135.36, 127.46, 126.75, 125.65, 122.89, 122.70, 122.28, 114.90, 108.16. HRMS (ESI) calculated for $C_{19}H_{15}N_5O$ (M+H)⁺: 330.1354, found 330.1348.

4.4.1. 2-(4-(pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (9i). Compound reported by (Tong *et al.*, 2009).

4.4.2. 2-(4-(5-(pyrrolidine-1-carbonyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (10a). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.22 (s, 1H), 8.90 (s, 1H), 8.80 (bs, NH), 8.71 (s, 1H), 8.37 (d, *J*=8.1, 2H), 8.07 (d, *J*=8.1, 2H), 7.91 (d, *J*=7.7, 1H), 7.86 (d, *J*=8.6, 1H), 7.47 (t, *J*=8.1, 1H), 3.48-3.43 (m, 4H), 1.82-1.79 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 167.20, 164.47, 150.96, 144.55, 143.21, 138.35, 138.20, 136.65, 135.39, 134.44, 129.64, 128.42, 126.31, 124.98, 124.76, 122.06, 117.21 49.18, 46.67, 26.19, 24.24. HRMS (ESI) calculated for $C_{24}H_{21}N_5O_2$ (M+H)⁺: 412.1773, found 412.1765.

4.4.3. 6-methyl-2-(4-(5-(pyrrolidine-1-carbonyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (10b). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.10 (bs, 1H), 9.04 (bs, NH), 8.76 (bs, 1H), 8.38 (s, 1H), 8.33 (d, *J*=8.6, 2H), 8.03 (d, *J*=8.6, 2H), 7.71 (s, 1H), 7.57 (s, 1H), 3.48-3.44 (m, 4H), 1.86-1.81 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 166.89, 165.91, 151.09, 147.94, 146.50, 138.65, 135.85, 134.30, 134.18, 133.55, 130.42, 129.35, 128.62, 128.24, 126.62, 125.43, 122.07, 115.99, 49.29, 46.63,

26.43, 24.46, 21.69. HRMS (ESI) calculated for $C_{25}H_{23}N_5O_2$ (M+H)⁺: 426.1929, found 426.1946.

4.4.4. 2-(4-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (10c). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.03 (bs, NH), 8.66 (bs, 1H), 8.37 (d, *J*=8.6, 2H), 8.33 (s, 1H), 8.07 (d, *J*=8.6, 2H), 7.95 (d, *J*=7.7, 1H), 7.90 (d, *J*=8.1, 1H), 7.83 (bs, 1H), 7.53 (t, *J*=8.1, 1H), 3.62 (m, 2H), 3.49 (m, 2H), 1.82 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 166.90, 165.35, 153.71, 151.07, 146.51, 140.53, 136.24, 134.03, 133.79, 129.98, 128.10, 125.30, 124.89, 124.25, 122.28, 117.00, 49.02, 46.97, 26.53, 23.98. HRMS (ESI) calculated for $C_{24}H_{21}N_5O_2$ (M+H)⁺: 412.1773, found 412.1761.

4.4.5. 6-methyl-2-(4-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (10d). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.10 (s, NH), 9.00 (s, 1H), 8.33 (d, *J*=8.6, 2H), 8.30 (dd, *J*=2.3, 8.2, 1H), 8.01 (d, *J*=8.2, 2H), 7.82 (d, *J*=8.2, 1H), 7.70 (s, 1H), 7.55 (s, 1H), 3.64 (t, *J*=6.3, 2H), 3.49 (t, *J*=6.8, 2H), 2.50 (t, *J*=5.4, 3H), 1.85-1.83 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 166.81, 165.75, 153.97, 151.21, 146.66, 138.91, 136.09, 135.80, 135.64, 133.22, 128.69, 128.44, 128.16, 125.26, 124.17, 122.18, 115.83, 49.09, 47.03, 26.65, 24.07, 21.75. HRMS (ESI) calculated for $C_{25}H_{23}N_5O_2$ (M+H)⁺: 426.1929, found 426.1935.

4.4.6. 2-(4-(pyridin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (10e). Compound reported by (Tong *et al.*, 2009).

4.4.7. 2-(2'-acetamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (10f). ¹H NMR (270MHz, CD₃OD): δ 8.19 (d, *J*=8.3, 2H), 7.92 (d, *J*=7.8, 1H), 7.68 (d, *J*=7.8, 1H), 7.52 (d, *J*=8.3, 2H), 7.48 (d, *J*=8.1, 1H), 7.36-7.30 (m, 3H), 7.22 (t, *J*=7.5, 1H), 1.98 (s, 3H). ¹³C NMR (67MHz, CD₃OD): δ 172.54, 153.64, 143.00, 138.24, 135.64, 131.40, 130.63, 129.55, 129.47, 128.45, 128.08, 127.97, 124.39, 123.50, 123.27, 122.56, 118.58, 22.90. HRMS (ESI) calculated for $C_{22}H_{18}N_4O_2$ (M+H)⁺: 371.1507, found 371.1505.

4.4.8. 2-(3'-acetamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (10g). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.49 (s, CONH₂), 10.10 (s, NH), 9.38 (s, NH), 8.33 (d, *J*=8.3, 2H), 7.99 (s, 1H), 7.88 (d, *J*=7.7, 1H), 7.83 (d, *J*=8.3, 2H), 7.74 (d, *J*=7.8, 1H), 7.60 (s, 1H), 7.42 (d, *J*=4.8, 2H), 7.34 (t, *J*=7.8, 1H), 2.07 (s, CH₃). ¹³C NMR (100MHz, DMSO-*d*₆): δ 168.56, 166.22, 151.60, 142.07, 141.55, 140.02, 139.66, 135.41, 129.48, 128.17, 127.54, 127.26, 123.02, 122.42, 121.54, 118.35, 117.28, 115.05, 24.07. HRMS (ESI) calculated for $C_{22}H_{18}N_4O_2$ (M+H)⁺: 371.1507, found 371.1509.

4.4.9. 2-(4'-acetamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (10h). ¹H NMR (270MHz, DMSO-*d*₆): δ 8.32 (d, *J*=8.4, 2H), 8.22 (d, *J*=7.8, 1H), 8.14 (d, *J*=8.1, 1H), 7.93 (d, *J*=8.4, 2H), 7.75 (d, *J*=8.6, 2H), 7.69 (d, *J*=8.6, 2H), 7.54 (bs, 1H), 2.21 (s, 3H). ¹³C NMR (100MHz, CD₃OD): δ 168.98, 167.10, 153.10, 142.02, 139.85, 133.94, 129.92, 129.04, 128.67, 127.79, 127.48, 126.84, 126.31, 125.17, 122.55, 119.85, 116.65, 24.54. HRMS (ESI) calculated for $C_{22}H_{18}N_4O_2$ (M+H)⁺: 371.1507, found 371.1508.

4.5.0. 2-(4'-(pyrrolidine-1-carbonyl)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (10i). ¹H NMR (400MHz, DMSO-*d*₆): δ 9.38 (bs, NH), 8.37 (d, *J*=8.4, 2H), 7.96 (d, *J*=8.4, 2H), 7.90 (d, *J*=7.2, 1H), 7.84 (d, *J*=8.4, 2H), 7.78 (d, *J*=8.0, 1H), 7.65 (d, *J*=8.0, 2H), 7.37 (t, *J*=7.2, 1H), 3.51-3.48 (m, 4H), 1.90-1.83 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 168.34, 166.79, 152.07, 141.63, 140.77, 137.14, 128.99, 128.75, 128.43, 128.36, 128.08, 127.94, 127.16, 127.05, 123.48, 122.92, 115.68, 49.10,

46.51, 26.53, 24.44. HRMS (ESI) calculated for $C_{25}H_{22}N_4O_2$ (M+H)⁺: 411.1820, found 411.1817.

4.5.1. 6-methyl-2-(4'-(pyrrolidine-1-carbonyl)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (11a). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.33 (s, CONH₂), 9.33 (s, NH), 8.31 (d, *J*=8.5, 2H), 7.93 (d, *J*=8.3, 2H), 7.83 (d, *J*=8.3, 2H), 7.70 (s, 1H), 7.64 (d, *J*=8.1, 2H), 7.53 (s, 1H), 3.48-3.26 (m, 4H, overlap), 1.87-1.82 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 167.86, 166.20, 151.02, 140.95, 140.28, 139.77, 136.61, 135.72, 132.02, 128.59, 128.23, 127.90, 127.39, 126.51, 124.38, 121.90, 114.82, 48.95, 46.00, 25.99, 23.92, 21.29. HRMS (ESI) calculated for $C_{26}H_{24}N_4O_2$ (M+H)⁺: 425.1977, found 425.1979.

4.5.2. 2-(4-(6-acetamidopyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (11b). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.48 (s, CONH₂), 10.67 (s, NH), 9.38 (s, NH), 8.77 (s, 1H), 8.34 (d, *J*=8.0, 2H), 8.21 (s, 2H), 7.97 (d, *J*=8.0, 2H), 7.89 (d, *J*=7.3, 1H), 7.81-7.75 (m, 1H), 7.36 (t, *J*=8.0, 1H), 2.13 (s, 3H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 169.96, 166.70, 152.32, 152.03, 146.42, 142.03, 139.24, 136.72, 135.88, 130.42, 128.63, 128.06, 127.39, 123.54, 122.91, 115.54, 113.72, 24.46. HRMS (ESI) calculated for $C_{21}H_{17}N_5O_2$ (M+H)⁺: 372.1460, found 372.1461.

4.5.3. 2-(4-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)phenyl)-1H-benzimidazole-4-carboxamide (11c). ¹H NMR (400MHz, CD₃OD): δ 8.79 (s, 1H), 8.52 (s, 1H), 8.26 (d, *J*=8.3, 2H), 8.15 (s, 1H), 7.92 (bd, 1H), 7.83 (d, *J*=8.3, 2H), 7.71, (bd, *J*=7.5, 1H), 3.84 (s, 2H), 2.69 (bs, 4H), 1.87 (bs, 4H). ¹³C NMR (67MHz, CD₃OD): δ 68.45, 57.61, 55.03, 24.10, 22.13. HRMS (ESI) calculated for $C_{24}H_{23}N_5O$ (M+H)⁺: 398.1980, found 398.1989.

4.5.4. 2-(4'-(3-(piperidin-1-yl)propoxy)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (11d). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.67 (s, CONH₂), 9.39 (bs, NH), 8.33 (d, *J*=8.3, 1H), 7.96 (d, *J*=8.0, 2H), 7.85 (bs, 1H), 7.72 (d, *J*=8.0, 2H), 7.66 (d, *J*=8.3, 2H), 7.33 (bs, 1H), 7.03 (d, *J*=8.5, 2H), 4.09 (bs, 2H), 2.92 (bs, 2H), 2.11 (bs, 2H), 1.70 (bs, 4H), 1.48 (bs, 2H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 167.35, 158.64, 143.68, 131.43, 129.95, 129.35, 128.12, 126.06, 115.05, 65.44, 53.83, 52.57, 24.12, 23.27, 22.21. HRMS (ESI) calculated for $C_{28}H_{30}N_4O_2$ (M+H)⁺: 455.2446, found 455.2441.

4.5.5. 2-(4'-(2-(piperidin-1-yl)ethoxy)-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (11e). ¹H NMR (400MHz, DMSO-*d*₆): δ 13.61 (bs, CONH₂), 9.42 (s, NH), 8.28 (d, *J*=7.5, 2H), 7.87 (d, *J*=6.8, 1H), 7.77 (d, *J*=8.3, 2H), 7.73 (d, *J*=7.5, 1H), 7.63 (d, *J*=8.3, 2H), 7.31 (t, *J*=7.5, 1H), 6.98 (d, *J*=8.3, 2H), 4.06 (t, *J*=5.3, 2H), 2.68 (t, *J*=5.3, 2H), 1.46 (t, *J*=5.3, 4H), 1.31 (bs, 2H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 166.88, 159.01, 152.30, 142.30, 135.97, 131.92, 130.43, 129.52, 128.37, 128.01, 127.82, 127.38, 127.08, 126.86, 123.44, 122.78, 115.54, 65.75, 57.51, 54.67, 25.66, 24.08, 21.74. HRMS (ESI) calculated for $C_{27}H_{28}N_4O_2$ (M+H)⁺: 441.2290, found 441.2291.

4.5.6. 2-(4'-(cyclopropanecarboxamido)-2',3-difluoro-[1,1'-biphenyl]-4-yl)-6-fluoro-1H-benzimidazole-4-carboxamide (11f). ¹H NMR (400MHz, DMSO-*d*₆): δ 10.60 (s, NH), 9.26 (s, NH), 8.35 (t, *J*=7.8, 1H), 7.99-7.60 (m, 5H), 7.43 (s, 1H), 7.41 (s, 1H), 1.80-1.75 (m, 1H), 0.84-0.81 (m, 4H). ¹³C NMR (100MHz, DMSO-*d*₆): δ 172.46, 165.10, 160.45, 160.42, 158.00, 157.97, 147.99, 141.44, 141.32, 138.44, 130.82, 130.50, 125.30, 124.05, 120.11, 116.39, 115.77, 115.27, 110.78, 106.43, 102.10, 14.84, 7.75. HRMS (ESI) calculated for $C_{24}H_{17}N_4F_3O_2$ (M+H)⁺: 451.1381, found 451.1378.

4.5.7. 6-fluoro-2-(4'-propionamido-[1,1'-biphenyl]-4-yl)-1H-benzimidazole-4-carboxamide (11g). ¹H NMR (400MHz,

DMSO- d_6): δ 10.03 (s, NH), 9.35 (s, NH), 8.27 (d, $J=8.0$, 2H), 7.86 (d, $J=8.3$, 2H), 7.24 (bs, 4H), 7.59 (s, 1H), 7.57 (s, 1H), 2.34 (q, $J=7.6$, 2H), 1.08 (t, $J=7.6$, 3H). ^{13}C NMR (100MHz, DMSO- d_6): δ 172.38, 165.20, 158.47, 152.47, 141.81, 139.54, 133.45, 128.27, 127.58, 127.36, 127.16, 126.82, 125.98, 123.31, 119.53, 110.30, 101.68, 29.68, 9.75. HRMS (ESI) calculated for $\text{C}_{23}\text{H}_{19}\text{N}_4\text{F}_2\text{O}_2$ (M+H) $^+$: 403.1570, found 403.1575.

4.5.8. 2-(3'-(cyclopropanecarboxamido)-3-fluoro-[1,1'-biphenyl]-4-yl)-6-fluoro-1H-benzimidazole-4-carboxamide (11h). ^1H NMR (270MHz, DMSO- d_6): δ 10.38 (s, NH), 9.27 (s, NH), 8.36 (t, $J=8.1$, 1H), 8.04 (s, 1H), 7.71-7.60 (m, 5H), 7.43 (s, 1H), 7.41 (s, 1H), 1.80 (m, 1H), 0.82 (m, 4H). ^{13}C NMR (67MHz, DMSO- d_6): δ 174.42, 165.36, 160.90, 158.47, 148.31, 144.92, 140.54, 138.71, 137.95, 136.25, 131.24, 130.03, 124.00, 123.64, 122.00, 119.73, 117.77, 116.12, 114.85, 111.14, 102.37, 15.08, 7.74. HRMS (ESI) calculated for $\text{C}_{24}\text{H}_{18}\text{N}_4\text{F}_2\text{O}_2$ (M+H) $^+$: 433.1475, found 433.1480.

4.5.9. 2-(4'-(cyclopropanecarboxamido)-3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)-6-fluoro-1H-benzimidazole-4-carboxamide (11i). ^1H NMR (400MHz, DMSO- d_6): δ 9.53 (s, NH), 9.27 (s, NH), 8.33 (t, $J=8.0$, 1H), 8.10 (d, $J=8.3$, 1H), 7.87 (d, $J=12.9$, 1H), 7.78 (dd, $J=1.7$, 8.3, 1H), 7.60 (bm, 2H), 7.44 (s, 1H), 7.37 (dd, $J=1.9$, 8.5, 1H), 3.98 (s, 3H), 2.12 (m, 1H), 0.80-0.76 (m, 4H). ^{13}C NMR (100MHz, DMSO- d_6): δ 172.08, 164.84, 160.48, 158.06, 149.56, 148.05, 144.20, 137.53, 135.84, 133.15, 130.55, 128.27, 123.45, 122.98, 121.81, 118.87, 115.17, 114.18, 110.60, 109.48, 101.92, 55.97, 14.26, 7.44. HRMS (ESI) calculated for $\text{C}_{25}\text{H}_{20}\text{N}_4\text{F}_2\text{O}_3$ (M+H) $^+$: 463.1581, found 463.1572.

4.6.0. 2-(4'-(cyclopropanecarboxamido)-3'-methoxy-[1,1'-biphenyl]-4-yl)-6-fluoro-1H-benzimidazole-4-carboxamide (11j). ^1H NMR (400MHz, DMSO- d_6): δ 9.51 (s, NH), 9.33 (s, NH), 8.30 (d, $J=8.3$, 2H), 8.07 (d, $J=7.5$, 1H), 7.92 (d, $J=7.5$, 2H), 7.60 (s, 1H), 7.57 (s, 1H), 7.40 (s, 1H), 7.31 (d, $J=8.3$, 2H), 3.98 (s, 3H), 2.12 (m, 1H), 0.81 (m, 4H). ^{13}C NMR (100MHz, DMSO- d_6): δ 171.99, 164.97, 159.55, 152.79, 149.62, 141.92, 138.28, 135.81, 134.68, 131.53, 127.38, 127.06, 121.97, 118.66, 109.36, 101.31, 55.88, 14.22, 7.81. HRMS (ESI) calculated for $\text{C}_{25}\text{H}_{21}\text{N}_4\text{F}_2\text{O}_3$ (M+H) $^+$: 445.1675, found 445.1680.

Acknowledgments

We would like to thank Aurigene Discovery Technologies (India) for their help in the *in-silico* studies and development of the project and Aurigene Discovery Technologies (Malaysia) for the PARP-1 and DHODH assay work. We would also like to thank Dr. Michael James Christopher Buckle for his review, proofreading and valuable discussions.


References and notes

- Ame, J. C., Spenlehauer, C., & de Murcia, G. (2004). The PARP superfamily. *Bioessays*, 26(8), 882-893. doi: 10.1002/bies.20085
- Baldwin, J., Michnoff, C. H., Malmquist, N. A., White, J., Roth, M. G., Rathod, P. K., & Phillips, M. A. (2005). High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. *J Biol Chem*, 280(23), 21847-21853. doi: 10.1074/jbc.M501100200
- Barkalow, J. H., Breting, J., Gaede, B. J., Haight, A. R., Henry, R., Kotecki, B., . . . Viswanath, S. K. (2007). Process Development for ABT-472, a Benzimidazole PARP Inhibitor. *Organic Process Research & Development*, 11(4), 693-698. doi: 10.1021/op7000194
- Batt, D. G., Copeland, R. A., Dowling, R. L., Gardner, T. L., Jones, E. A., Orwat, M. J., . . . Jaffee, B. D. (1995). Immunosuppressive structure-activity relationships of Brequinar and related cinchoninic acid derivatives. *Bioorg Med Chem Lett*, 5(14), 1549-1554. doi: http://dx.doi.org/10.1016/0960-894X(95)00252-0
- Batt, D. G., Petraitis, J. J., Sherk, S. R., Copeland, R. A., Dowling, R. L., Taylor, T. L., . . . Jaffee, B. D. (1998). Heteroatom- and carbon-linked biphenyl analogs of Brequinar as immunosuppressive agents. *Bioorg Med Chem Lett*, 8(13), 1745-1750. doi: http://dx.doi.org/10.1016/S0960-894X(98)00308-4
- Bonn, D. (2002). Prostate-cancer screening targets men with BRCA mutations. *The Lancet Oncology*, 3(12), 714. doi: 10.1016/s1470-2045(02)00950-6
- Caiafa, P., Guastafierro, T., & Zampieri, M. (2009). Epigenetics: poly(ADP-ribose)ylation of PARP-1 regulates genomic methylation patterns. *The FASEB Journal*, 23(3), 672-678. doi: 10.1096/fj.08-123265
- Calabrese, C. R., Almasy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., . . . Curtin, N. J. (2004). Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361. *Journal of the National Cancer Institute*, 96(1), 56-67. doi: 10.1093/jnci/djh005
- Chen, S.-F., Ruben, R. L., & Dexter, D. L. (1986). Mechanism of Action of the Novel Anticancer Agent 6-Fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic Acid Sodium Salt (NSC 368390): Inhibition of de Novo Pyrimidine Nucleotide Biosynthesis. *Cancer Res*, 46(10), 5014-5019.
- David, K. K., Andrabi, S. A., Dawson, T. M., & Dawson, V. L. (2009). Parthanatos, a messenger of death. *Front Biosci (Landmark Ed)*, 14, 1116-1128.
- De Lorenzo, S., Patel, A., Hurley, R., & Kaufmann, S. H. (2013). The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. *Front Oncol*, 3. doi: 10.3389/fonc.2013.00228
- Dexter, D. L., Hesson, D. P., Ardecky, R. J., Rao, G. V., Tippett, D. L., Dusak, B. A., . . . Forbes, M. (1985). Activity of a Novel 4-Quinolinecarboxylic Acid, NSC 368390 [6-Fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic Acid Sodium Salt], against Experimental Tumors. *Cancer Res*, 45(11 Part 1), 5563-5568.
- Evans, D. R., & Guy, H. I. (2004). Mammalian Pyrimidine Biosynthesis: Fresh Insights into an Ancient Pathway. *Journal of Biological Chemistry*, 279(32), 33035-33038. doi: 10.1074/jbc.R400007200
- Fatokun, A. A., Dawson, V. L., & Dawson, T. M. (2014). Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. *Br J Pharmacol*, 171(8), 2000-2016. doi: 10.1111/bph.12416
- Griffin, R. J., Srinivasan, S., Bowman, K., Calvert, A. H., Curtin, N. J., Newell, D. R., . . . Golding, B. T. (1998). Resistance-Modifying Agents. 5.1 Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP). *J Med Chem*, 41(26), 5247-5256. doi: 10.1021/jm980273t
- Herrmann, M. L., Schleyerbach, R., & Kirschbaum, B. J. (2000). Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. *Immunopharmacology*, 47(2-3), 273-289.
- Kummar, S., Chen, A., Parchment, R., Kinders, R., Ji, J., Tomaszewski, J., & Doroshow, J. (2012). Advances in using PARP inhibitors to treat cancer. *BMC Medicine*, 10(1), 25.
- Messner, S., & Hottiger, M. O. (2011). Histone ADP-ribosylation in DNA repair, replication and transcription. *Trends in Cell Biology*, 21(9), 534-542. doi: http://dx.doi.org/10.1016/j.tcb.2011.06.001
- Munier-Lehmann, H., Vidalain, P. O., Tangy, F., & Janin, Y. L. (2013). On dihydroorotate dehydrogenases and their inhibitors and uses. *J Med Chem*, 56(8), 3148-3167. doi: 10.1021/jm301848w
- Penning, T. D., Zhu, G. D., Gandhi, V. B., Gong, J., Liu, X., Shi, Y., . . . Giranda, V. L. (2009). Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. *J Med Chem*, 52(2), 514-523. doi: 10.1021/jm801171j
- Penning, T. D., Zhu, G. D., Gandhi, V. B., Gong, J., Thomas, S., Lubisch, W., . . . Giranda, V. L. (2008). Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer. *Bioorg Med Chem*, 16(14), 6965-6975. doi: 10.1016/j.bmc.2008.05.044
- Quénet, D., El Ramy, R., Schreiber, V., & Dantzer, F. (2009). The role of poly(ADP-ribose)ylation in epigenetic events. *The International Journal of Biochemistry & Cell Biology*, 41(1), 60-65. doi: http://dx.doi.org/10.1016/j.biocel.2008.07.023


23. Refaat, H. M. (2010). Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives. *Eur J Med Chem*, 45(7), 2949-2956. doi: 10.1016/j.ejmech.2010.03.022
24. Sousa, F. G., Matuo, R., Soares, D. G., Escargueil, A. E., Henriques, J. A. P., Larsen, A. K., & Saffi, J. (2012). PARPs and the DNA damage response. *Carcinogenesis*, 33(8), 1433-1440. doi: 10.1093/carcin/bgs132
25. Suto, M. J., Turner, W. R., Arundel-Suto, C. M., Werbel, L. M., & Sebolt-Leopold, J. S. (1991). Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. *Anticancer Drug Des*, 6(2), 107-117.
26. Thunuguntla, S. S. R., Subramanya, H., Kunnam, S. R., Sanivaru, V. S. R., Bingi, C., Kusanur, R., . . . Arlt, M. (2010). Dihydroorotate dehydrogenase inhibitors: Google Patents.
27. Tong, Y., Bouska, J. J., Ellis, P. A., Johnson, E. F., Leverson, J., Liu, X., . . . Penning, T. D. (2009). Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents. *J Med Chem*, 52(21), 6803-6813. doi: 10.1021/jm900697r
28. Underhill, C., Toulmonde, M., & Bonnefoi, H. (2010). A review of PARP inhibitors: from bench to bedside. *Annals of Oncology*. doi: 10.1093/annonc/mdq322
29. White, A. W., Almassy, R., Calvert, A. H., Curtin, N. J., Griffin, R. J., Hostomsky, Z., . . . Golding, B. T. (2000). Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. *J Med Chem*, 43(22), 4084-4097.
30. White, A. W., Curtin, N. J., Eastman, B. W., Golding, B. T., Hostomsky, Z., Kyle, S., . . . Griffin, R. J. (2004). Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. *Bioorg Med Chem Lett*, 14(10), 2433-2437. doi: 10.1016/j.bmcl.2004.03.017
31. Zhu, G. D., Gong, J., Gandhi, V. B., Liu, X., Shi, Y., Johnson, E. F., . . . Penning, T. D. (2012). Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer. *Bioorg Med Chem*, 20(15), 4635-4645. doi: 10.1016/j.bmc.2012.06.021

Supplementary material.
Supplementary material.

Figure(s)



Scheme 1. Side chain preparation from phenyl ester 1



Scheme 2. General strategy for the synthesis of benzimidazole carboxamide and carboxylic acid derivatives




Figure 1. Docking modes showing the interactions of compounds II (A) and 9a (B) in DHODH (pdb ID: 4IGH) and PARP-1 (pdb ID: 4HHZ) respectively




Figure 2. Structure and biochemical activity of compounds 9a and 9b.




Figure 3. Docking modes showing the interactions of compound 10g in DHODH (A, pdb ID: 4IGH) and PARP-1 (B, pdb ID: 4HHZ) respectively.




Figure 4. Summary of the SAR points for possible dual inhibition of DHODH and PARP-1 enzymes.


Table(s)

Table 1. Chemical structure of benzimidazole carboxylic acid derivatives synthesized via Scheme 2

Entry	Compound
7a	
7b	
7c	
7d	
7e	
7f	
7g	

Table 2. Chemical structure of benzimidazole carboxamide derivatives synthesized via Scheme 2.

Entry	Product	Entry	Product	Entry	Product
9a ^a		10a		11a	
9b		10b		11b	
9c ^b		10b		11c	
9d		10d		11d	
9e ^b		10e ^a		11e	
9f		10f		11f	
9g		10g		11g	



^aCompounds reported by Tong and group (Tong et al., 2009).

^bCompounds reported by Alex and group (White et al., 2000).

Table 3. PARP and DHODH inhibition by benzimidazole derivatives. The activity is expressed as percent inhibition at 10 μM or IC_{50} values.

Entry	R ₁	R ₂	R ₃	R ₄	R ₅	PARP-1	DHODH
						IC_{50} (μM) / % inhibition at 10 μM	IC_{50} (μM) / % inhibition at 10 μM
Veliparib (ABT-888)						0.005	-
Brequinar						-	0.012
9a	NH ₂	H	H	H		0.71	9.80
9b	NH ₂	CH ₃	H	H		28%	7.80
9c	NH ₂	H	H	H		N.A	N.A
9d	NH ₂	CH ₃	H	H		N.A	N.A
9e	NH ₂	H	H	H		N.A	N.A
9f	NH ₂	CH ₃	H	H		N.A	N.A
9g	NH ₂	CH ₃	H	H		N.A	N.A
9h	NH ₂	H	H	H		0.032	20%
9i	NH ₂	H	H	H		0.022	19%
10a	NH ₂	H	H	H		0.029	28%
10b	NH ₂	CH ₃	H	H		N.A	50%
10c	NH ₂	H	H	H		0.012	N.A
10d	NH ₂	CH ₃	H	H		17%	37%
10e	NH ₂	H	H	H		0.083	28%
10f	NH ₂	H	H	H		0.14	51%

Continue from Table 3

10g	NH ₂	H	H	H		0.46	42%
10h	NH ₂	H	H	H		16%	56%

10i	NH ₂	H	H	H		0.31	20%
11a	NH ₂	CH ₃	H	H		N.A	N.A
11b	NH ₂	H	H	H		0.049	40%
11c	NH ₂	H	H	H		0.061	55%
11d	NH ₂	CH ₃	H	H		2.28	N.A
11e	NH ₂	H	H	H		0.72	31%
11f	NH ₂	F	F	H		0.084	48%
11g	NH ₂	F	H	H		1.72	N.A
11h	NH ₂	F	F	H		1.28	38%
11i	NH ₂	F	F	H		0.98	23%
11j	NH ₂	F	H	H		5.96	N.A
7a	OH	CH ₃	H	H		N.A	0.21
7b	OH	CH ₃	H	H		N.A	1.38
7c	OH	CH ₃	H	H		N.A	32%
7d	OH	CH ₃	H	H		10.63	0.30
7e	OH	CH ₃	H	H		N.A	0.028
7f	OH	CH ₃	H	H		44%	0.013
7g	OH	CH ₃	H	NHAc		N.A	47%

*N.A. – Not active

Graphical Abstract

